Coronary Artery Disease: Taylor AJ

Oudkerk M, Stillman AE, Halliburton SS, Kalender WA, Möhlenkamp S, McCollough CH, Vliegenthart R, Shaw LJ, Stanford W, Taylor AJ, van Ooijen PM, Wexler L, Raggi P, Anonymous00008, Anonymous00009. · Department of Radiology, Groningen University Hospital, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. · Eur Radiol. · Pubmed #18651153 No free full text.

Abstract: Current guidelines and literature on screening for coronary artery calcium for cardiac risk assessment are reviewed for both general and special populations. It is shown that for both general and special populations a zero score excludes most clinically relevant coronary artery disease. The importance of standardization of coronary artery calcium measurements by multidetector CT is discussed.

Mieres JH, Shaw LJ, Arai A, Budoff MJ, Flamm SD, Hundley WG, Marwick TH, Mosca L, Patel AR, Quinones MA, Redberg RF, Taubert KA, Taylor AJ, Thomas GS, Wenger NK, Anonymous00198. · No affiliation provided · Circulation. · Pubmed #15687114 links to  free full text

Abstract: Cardiovascular disease is the leading cause of mortality for women in the United States. Coronary heart disease, which includes coronary atherosclerotic disease, myocardial infarction, acute coronary syndromes, and angina, is the largest subset of this mortality, with >240,000 women dying annually from the disease. Atherosclerotic coronary artery disease (CAD) is the focus of this consensus statement. Research continues to report underrecognition and underdiagnosis of CAD as contributory to high mortality rates in women. Timely and accurate diagnosis can significantly reduce CAD mortality for women; indeed, once the diagnosis is made, it does appear that current treatments are equally effective at reducing risk in both women and men. As such, noninvasive diagnostic and prognostic testing offers the potential to identify women at increased CAD risk as the basis for instituting preventive and therapeutic interventions. Nevertheless, the recent evidence-based practice program report from the Agency for Healthcare Research and Quality noted the paucity of women enrolled in diagnostic research studies. Consequently, much of the evidence supporting contemporary recommendations for noninvasive diagnostic studies in women is extrapolated from studies conducted predominantly in cohorts of middle-aged men. The majority of diagnostic and prognostic evidence in cardiac imaging in women and men has been derived from observational registries and referral populations that are affected by selection and other biases. Thus, a better understanding of the potential impact of sex differences on noninvasive cardiac testing in women may greatly improve clinical decision making. This consensus statement provides a synopsis of available evidence on the role of the exercise ECG and cardiac imaging modalities, both those in common use as well as developing technologies that may add clinical value to the diagnosis and risk assessment of the symptomatic and asymptomatic woman with suspected CAD.

Taylor AJ, Weissman G. · No affiliation provided · J Cardiovasc Comput Tomogr. · Pubmed #19278913 No free full text.

This publication has no abstract.

Gerber TC, Taylor AJ. · No affiliation provided · Mayo Clin Proc. · Pubmed #19252107 No free full text.

This publication has no abstract.

Taylor AJ, Raggi J, Raggi P. · No affiliation provided · J Cardiovasc Comput Tomogr. · Pubmed #19083901 No free full text.

This publication has no abstract.

Oudkerk M, Stillman AE, Halliburton SS, Kalender WA, Möhlenkamp S, McCollough CH, Vliegenthart R, Shaw LJ, Stanford W, Taylor AJ, van Ooijen PM, Wexler L, Raggi P. · Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. · Int J Cardiovasc Imaging. · Pubmed #18504647 links to  free full text

Abstract: Current guidelines and literature on screening for coronary artery calcium for cardiac risk assessment are reviewed for both general and special populations. It is shown that for both general and special populations a zero score excludes most clinically relevant coronary artery disease. The importance of standardization of coronary artery calcium measurements by multi-detector CT is discussed.

Taylor AJ. · Cardiology Service, Department of Medicine, Walter Reed Army Medical Center, Washington, District of Columbia 20307-5001, USA. · Am J Cardiol. · Pubmed #18375240 No free full text.

Abstract: High-density lipoprotein (HDL) is a "regression particle" based on its unique lipid particle biology. This unique property predicts that, in theory, therapies that raise HDL cholesterol should be able to induce regression of atherosclerosis. Presently, the principle pharmacotherapy for increasing HDL cholesterol is niacin. Niacin has been shown to regress atherosclerosis when used as monotherapy, in combination with a statin, and in combination with nonstatin therapies (including cholesterol-binding resins) and fibrates. Insights into the atherosclerosis benefits of combination lipid-lowering therapy with niacin have come from imaging studies utilizing quantitative coronary angiography, carotid ultrasound, and intravascular ultrasound showing modest inverse correlations between the extent of HDL increase and atherosclerosis regression. Recent adverse atherosclerosis and clinical effects seen with cholesterol ester transfer protein inhibition indicate that HDL-raising effects alone are insufficient to predict clinical benefit of new HDL therapies. Thus, although clinical trial evidence is necessary to understand the full scope of the safety and efficacy profile of novel HDL therapeutics, atherosclerosis imaging will be an important component of preclinical testing of these agents as they emerge and in head-to-head testing of treatment strategies.

Devine PJ, Carlson DW, Taylor AJ. · Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · J Nucl Cardiol. · Pubmed #16945751 No free full text.

Abstract: Carotid intima-media thickness (CIMT) testing is recognized as a valid method for the noninvasive assessment of atherosclerosis. In addition to its association with known cardiovascular risk factors and both prevalent and incident coronary heart disease, the rate of CIMT progression is directly related to the risk for future cardiovascular events. Subsequently, CIMT has been a valuable research tool in clinical trials in the assessment of therapeutic agents directed against atherosclerosis. An overview of CIMT testing including its precise measurement, establishment as a surrogate for atherosclerosis by epidemiologic trials, role in clinical trials, and potential applications in both primary and secondary coronary heart disease prevention is presented.

Taylor AJ. · Department of Medicine and Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA. · Am J Cardiol. · Pubmed #12459419 No free full text.

Abstract: Atherosclerosis imaging techniques, such as coronary computed tomography, carotid ultrasound, and vascular magnetic resonance imaging, accurately measure the extent of subclinical atherosclerosis as a biomarker of the effects of an individual patient's coronary risk factors. Among the many potential applications of these tests, their greatest public health impact will be their use in the detection and management of cardiovascular risk. A growing body of data supports the application of these tests for the detection of cardiovascular risk, although further work is needed to document their additive diagnostic and management impact over measured risk factors and the global risk assessment. Each of these tests has a high degree of accuracy and reproducibility, creating the potential for serial imaging as a way to monitor cardiovascular risk by the detection of atherosclerosis progression, which is a known marker for an adverse cardiovascular prognosis.

Burke AP, Weber DK, Kolodgie FD, Farb A, Taylor AJ, Virmani R. · Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC, USA. · Herz. · Pubmed #11479935 No free full text.

Abstract: BACKGROUND AND MORPHOLOGIC STUDIES: Because coronary artery calcification correlates highly with plaque burden, it is an excellent disease marker for atherosclerosis. However, it is not a sensitive indicator of disease activity, and does not predict luminal compromise because of compensatory remodeling. In addition, most data do not support the concept that plaque calcification is related to plaque instability. Plaques demonstrating acute rupture usually show mild or moderate calcification, and biophysical models do not predict that calcium should result in an increased propensity to rupture. This review outlines morphologic studies relating calcification to risk factors and coronary plaque morphology.

Taylor AJ, O'Malley PG. · Department of Medicine (Cardiology Service and General Internal Medicine Service), Walter Reed Army Medical Center, Washington, DC, USA. · West J Med. · Pubmed #10639871 links to  free full text

This publication has no abstract.

O'Malley PG, Taylor AJ, Gibbons RV, Feuerstein IM, Jones DL, Vernalis M, Brazaitis M. · Department of Medicine, the Cardiology Service, Walter Reed Army Institute of Research, Washington, DC, USA. · Am Heart J. · Pubmed #10220644 No free full text.

Abstract: BACKGROUND: Screening for coronary artery calcium with electron beam computed tomography (EBCT) has potential diagnostic and prognostic implications. Most prior research on this technology has been done on selected, high-risk populations. The goal of the Prospective Army Coronary Calcium (PACC) study is to determine the utility of EBCT for the detection of coronary calcium as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty personnel undergoing the United States Army's Cardiovascular Screening Program. METHODS AND RESULTS: Three study designs will be used to address the objectives of this investigation: (1) a cross-sectional study of 2000 unselected, consecutive participants to determine the prevalence and extent of coronary calcification in the 40- to 45-year-old Army population, (2) a randomized, controlled trial with a 2 x 2 factorial design involving 1000 participants to assess the impact of EBCT information on several dimensions of patient behavior, with and without intensive risk factor case management, and (3) a prospective cohort study of 2000 participants followed for at least 5 years to establish the relation between coronary calcification and cardiovascular events in an unselected, "low-risk" (by conventional standards) Army population. CONCLUSIONS: We present a review of the literature on the clinical utility of EBCT, with a focus on the limited research in young, asymptomatic populations. The details of the PACC study (begun in October1998) are presented. The results of the PACC study will determine the clinical utility of EBCT in young, asymptomatic patients.

Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. · Cardiovascular Research, Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Ave, NW, Bldg 2, Room 3L28, Washington, DC 20307-5001, USA. · Circulation. · Pubmed #15537681 links to  free full text

Abstract: BACKGROUND: Niacin reduces coronary heart disease morbidity and mortality when taken either alone or in combination with statins; however, the incremental impact of adding niacin to background statin therapy is unknown. METHODS AND RESULTS: This was a double-blind randomized placebo-controlled study of once-daily extended-release niacin (1000 mg) added to background statin therapy in 167 patients (mean age 67 years) with known coronary heart disease and low levels of high-density lipoprotein cholesterol (HDL-C; <45 mg/dL). The primary end point was the change in common carotid intima-media thickness (CIMT) after 1 year. Baseline CIMT (0.884+/-0.234 mm), low-density lipoprotein cholesterol (89+/-20 mg/dL), and HDL-C (40+/-7 mg/dL) were comparable in the placebo and niacin groups. Adherence to niacin exceeded 90%, and 149 patients (89.2%) completed the study. HDL-C increased 21% (39 to 47 mg/dL) in the niacin group. After 12 months, mean CIMT increased significantly in the placebo group (0.044+/-0.100 mm; P<0.001) and was unchanged in the niacin group (0.014+/-0.104 mm; P=0.23). Although the overall difference in IMT progression between the niacin and placebo groups was not statistically significant (P=0.08), niacin significantly reduced the rate of IMT progression in subjects without insulin resistance (P=0.026). Clinical cardiovascular events occurred in 3 patients treated with niacin (3.8%) and 7 patients treated with placebo (9.6%; P=0.20). CONCLUSIONS: The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.

O'Malley PG, Feuerstein IM, Taylor AJ. · Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · JAMA. · Pubmed #12734132 links to  free full text

Abstract: CONTEXT: Although the use of electron beam tomography (EBT) as a motivational tool to change behavior is practiced, its efficacy has not been studied. OBJECTIVE: To assess the effects of incorporating EBT as a motivational factor into a cardiovascular screening program in the context of either intensive case management (ICM) or usual care by assessing its impact over 1 year on a composite measure of projected risk. DESIGN: Randomized controlled trial with a 2 x 2 factorial design and 1 year of follow-up. SETTING AND PARTICIPANTS: A consecutive sample of 450 asymptomatic active-duty US Army personnel aged 39 to 45 years stationed within the Washington, DC, area and scheduled to undergo a periodic Army-mandated physical examination were enrolled between January 1999 and March 2001 (mean age, 42 years; 79% male; 66 [15%] had coronary calcification; mean [SD] predicted 10-year coronary risk, 5.85% [3.85%]). INTERVENTIONS: Patients were randomly assigned to 1 of 4 intervention arms: EBT results provided in the setting of either ICM (n = 111) or usual care (n = 119) or EBT results withheld in the setting of either ICM (n = 124) or usual care (n = 96). MAIN OUTCOME MEASURE: The primary outcome measure was change in a composite measure of risk, the 10-year Framingham Risk Score (FRS). RESULTS: Comparing the groups who received EBT results with those who did not, the mean absolute risk change in 10-year FRS was +0.30 vs +0.36 (P =.81). Comparing the groups who received ICM with those who received usual care, the mean absolute risk change in 10-year FRS was -0.06 vs +0.74 (P =.003). Improvement or stabilization of cardiovascular risk was noted in 157 patients (40.2%). In multivariable analyses predicting change in FRS, after controlling for knowledge of coronary calcification, motivation for change, and multiple psychological variables, only the number of risk factors (odds ratio, 1.42; 95% confidence interval, 1.16-1.75 for each additional risk factor) and receipt of ICM (odds ratio, 1.62; 95% confidence interval, 1.04-2.52) were associated with improved or stabilized projected risk. CONCLUSIONS: Using coronary calcification screening to motivate patients to make evidence-based changes in risk factors was not associated with improvement in modifiable cardiovascular risk at 1 year. Case management was superior to usual care in the management of risk factors.

Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. · Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, and USA. · Circulation. · Pubmed #12379573 links to  free full text

Abstract: BACKGROUND: Whether marked LDL reduction to levels well below 100 mg/dL would further reduce the burden of cardiovascular disease is controversial. We compared the effects of 2 statins with widely differing potencies for LDL reduction (pravastatin 40 mg/d and atorvastatin 80 mg/d) on carotid intima-media thickness (CIMT). METHODS AND RESULTS: This was a single-center, randomized, clinical trial of 161 patients (mean age, 60 years; 71.4% male; 46% with known cardiovascular disease) that met National Cholesterol Education Program (NCEP) II criteria for lipid-lowering therapy. The effects of atorvastatin (80 mg/d; n=79) and pravastatin (40 mg/d; n=82) on CIMT were compared using blinded, serial assessments of the far wall of the distal common carotid artery. Baseline CIMT and other characteristics were similar between study groups. As anticipated, atorvastatin was substantially more potent for LDL reduction after 12 months: in the atorvastatin group, LDL cholesterol was 76+/-23 mg/dL after 12 months (-48.5%); LDL cholesterol was 110+/-30 mg/dL in the pravastatin group (-27.2%; P<0.001). Atorvastatin induced progressive CIMT regression over 12 months (change in CIMT, -0.034+/-0.021 mm), whereas CIMT was stable in the pravastatin group (change of 0.025+/- 0.017 mm; P=0.03). CONCLUSIONS: Marked LDL reduction (<100 mg/dL) with a high-potency statin provides superior efficacy for atherosclerosis regression at 1 year. This early effect on CIMT, a surrogate for clinical benefit, suggests that marked LDL reduction with synthetic statins may provide enhanced reduction in clinical coronary event rates.

Markwood TT, Kent SM, Coyle LC, Flaherty PJ, O'Malley PG, Taylor AJ. · Cardiology and General Internal Medicine Services, Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · Am Heart J. · Pubmed #11231429 No free full text.

Abstract: BACKGROUND: As a class, statins are remarkably effective in reducing low-density lipoprotein (LDL) cholesterol, and several of these drugs have now been shown to reduce coronary heart disease morbidity and mortality. However, several important controversies in the use of statins remain to be answered by clinical trials. For example, it is controversial whether marked cholesterol reduction to levels below 100 mg/dL would further reduce the incidence of coronary heart disease. Furthermore, concerns about differences among statins for nonlipid effects has raised the concern that the assumption of a class effect is premature until head-to-head clinical trials are completed. METHODS: Arterial Biology for the Investigation for the Treatment Effects of Reducing Cholesterol (ARBITER) is a single-center, randomized, active-controlled study comparing the efficacy of high-dose atorvastatin (80 mg/d) and pravastatin (40 mg/d) in patients being treated for either the primary or secondary prevention of coronary heart disease. This trial will enroll up to 200 patients for the primary end point of the mean change in intima-media thickness of the common carotid artery. This effect will be evaluated over a treatment duration of 12 months. Secondary end points include the effects of statin therapy on inflammatory and hemostatic markers (C-reactive protein and fibrinogen). CONCLUSION: ARBITER will provide important data on the role of marked LDL reduction and the "class effect" theory of statin therapy in cardiovascular medicine.

Taylor AJ, Wu H, Bindeman J, Bauer K, Byrd C, O'Malley PG, Feuerstein I. · Department of Medicine and Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA. · J Cardiovasc Comput Tomogr. · Pubmed #19217367 No free full text.

Abstract: BACKGROUND: Although African Americans have a lower prevalence and extent of coronary artery calcium (CAC) than whites, the relationship between ethnicity and CAC progression is unknown. In a prospective rescan substudy of the Prospective Army Coronary Calcium (PACC) Project, we evaluated ethnic differences in the rates of CAC progression over 4 years. METHODS: Two hundred healthy male PACC Project participants (age, 47.8 +/- 2.8 years) with CAC on their original scan volunteered to undergo a second electron beam tomography (EBT) scan and cardiovascular risk factor assessment (interscan interval, 4.3 +/- 1.2 y). All results were independently examined and blinded to baseline data. A change in CAC score >or=15%/y was defined as clinically significant progression. The relationship between race and CAC progression was evaluated with multivariable linear and logistic regression models controlling for age and other cardiovascular risk factors. RESULTS: African Americans had significantly lower baseline CAC scores (34.3 vs 101.5; P = 0.004); lower follow-up CAC scores (56.6 vs 180.6; P = 0.001); and worse cardiovascular risk profiles. The annualized CAC progression rate was not significantly related to race in the multivariable linear regression model controlling for age, the Framingham risk score, and other cardiovascular risk factors. Significant CAC progression occurred in 43.5% of all participants. The incidence of significant progression of CAC for African American and white men was similar (53.1% vs 52.4%; P = 0.94), even when controlling for age, the Framingham risk score, and other cardiovascular risk factors. CONCLUSION: Although African American men have less CAC than white men, CAC progression occurs at a comparable rate over 4 years.

Taylor AJ, Rodriguez AE, Lee JC, Mathew SB, Cassimatis D, Gates D, Bindeman J, Feuerstein IM, Do SW, O'Malley PG. · Cardiology Service, Department of Medicine and Radiology, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · Biomarkers. · Pubmed #18608184 No free full text.

Abstract: Electrocardiographic findings indicating myocardial disease, such as left ventricular hypertrophy or ST-T wave abnormalities, or the presence of coronary artery calcium, indicating atherosclerotic coronary artery disease, are both biomarkers of future cardiovascular (CV) risk. Although the risk factors for myocardial and coronary artery disease are similar, their concomitant expression has implications for CV disease screening and prevention programmes. The relationship between the resting 12-lead ECG and subclinical atherosclerosis measured as coronary artery calcium (CAC) with electron beam tomography was examined in 937 healthy participants (aged 40-50 years) enrolled in a CV risk screening study. Electrocardiograms and CAC were interpreted in blinded fashion, using standard criteria. An abnormal ECG was coded in 268 (28.6%) participants, most commonly left ventricular hypertrophy (3.1%), delayed precordial R wave transition (5.7%), T-wave abnormalities (10.0%) and intraventricular conduction delay (10.4%). Although abnormal ECG findings were associated with CV risk variables, the prevalence of any CAC was similar in subjects with any ECG finding (43 of 268, 16.0%) compared with those with normal ECGs (125 of 669, 18.7%, p =NS). In a logistic model controlling for CV risk factors including systolic blood pressure, low-density lipoprotein cholesterol (LDL-C), body mass index (BMI), glycosylated haemoglobin, race, age and gender, significant associations with CAC were found for LDL-C, race and BMI. There was no significant relationship between CAC and ECG abnormalities (odds ratio 0.80, 95% confidence interval 0.54-1.20). In conclusion, electrocardiographic abnormalities and subclinical calcified atherosclerosis were not significantly associated with each other in this middle-aged screening population. This suggests these two biomarkers may be complementary towards broader detection of latent CV risk.

Taylor AJ, Bindeman J, Feuerstein I, Le T, Bauer K, Byrd C, Wu H, O'Malley PG. · Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · J Am Coll Cardiol. · Pubmed #18387433 No free full text.

Abstract: OBJECTIVES: We examined the association of coronary artery calcium (CAC) detected on a screening exam with subsequent statin and aspirin usage in a healthy male screening cohort. BACKGROUND: Whether the presence of CAC, an independent predictor of coronary heart disease outcomes, alters clinical management, such as the use of preventive medications, is unknown. METHODS: Men (n = 1,640) ages 40 to 50 years (mean 42 years) were screened for coronary heart disease risk factors and CAC. The CAC scores and risk factors were reported to patients, and results were made available in the electronic medical record; however, medications were not prescribed or recommended by the study. During up to 6 years of subsequent annual structured telephone follow-up, we observed the community-based initiation and persistence of aspirin and statin therapy. RESULTS: A progressive increase in the incidence of pharmacotherapy was noted over time such that those with CAC were 3 times more likely to receive a statin (48.5% vs. 15.5%, p < 0.001) and also significantly more likely to receive aspirin (53.0% vs. 32.3%; p < 0.001) than those without CAC. In multivariable models controlling for National Cholesterol Education Program risk variables and baseline medication use, CAC was strongly and independently associated with use of either statin (odds ratio [OR] 3.53; 95% confidence interval [CI] 2.66 to 4.69), aspirin (OR 3.05; 95% CI 2.30 to 4.05) or both (OR 6.97; 95% CI 4.81 to 10.10). CONCLUSIONS: In this prospective cohort, the presence of coronary calcification was associated with an independent 3-fold greater likelihood of statin and aspirin usage.

Taylor AJ, Bindeman J, Le TP, Bauer K, Byrd C, Feuerstein IM, Wu H, O'Malley PG. · Department of Medicine and Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · Atherosclerosis. · Pubmed #17727858 No free full text.

Abstract: BACKGROUND: The determinants of coronary artery calcium (CAC) progression are not well understood. Prior studies have shown a limited relationship between CAC progression and traditional coronary risk factors. We hypothesized that the extent of non-calcified atherosclerosis detected using carotid intima-media thickness (CIMT) would predict progression of calcified atherosclerosis. METHODS: One hundred and eighty healthy male participants (mean age 47.9) with CAC from the Prospective Army Coronary Calcium (PACC) project volunteered to undergo a second EBCT scan, risk factor assessment, lab testing, and CIMT assessment 4.2+/-1.3 years after their original scan. All results were independently examined, blinded to baseline data. A change in CAC score >or=15% per year was defined as clinically significant progression. RESULTS: CAC progression occurred in 60.2%. Compared to participants without progression, those with progression had higher triglycerides, LDL and total cholesterol and Framingham risk scores, but similar blood pressure, HDL cholesterol, blood glucose, C-reactive protein, fibrinogen, and body mass index. CIMT was significantly higher among those with versus without CAC progression (0.660 mm versus 0.603 mm; P=0.001). Each quintile of increasing CIMT was independently associated with a 35% increase in the odds of CAC progression (P=0.01), after controlling for the Framingham risk score and C-reactive protein. CONCLUSION: Among middle-aged men with coronary calcium, increasing extent of non-calcified atherosclerosis is strongly associated with coronary artery calcium progression over 4 years.

Bellasi A, Lacey C, Taylor AJ, Raggi P, Wilson PW, Budoff MJ, Vaccarino V, Shaw LJ. · Emory University School of Medicine, Atlanta, Georgia, USA. · Am J Cardiol. · Pubmed #17659919 No free full text.

Abstract: Women with coronary heart disease (CHD) have higher mortality compared with men. Atherosclerotic imaging risk markers are associated with higher mortality and relative risk of CHD events in women compared with men. However, data on the predictive accuracy of coronary artery calcium (CAC) in women are scarce. We performed a systematic review of the published literature from 2003 to 2006 on the prognostic value of CAC in women and men. Two investigators reviewed Medline for prospective registries on annual rates of CHD death or myocardial infarction (MI) by CAC results. Three studies in 6,481 women and 13,697 men reported results by gender. We also analyzed 2 observational registries for annual all-cause death rates by CAC scores in women (n = 17,779) and men (n = 17,850). Summary relative risk ratios and 95% confidence intervals were calculated using a random effects model. For all-cause mortality, rates were 0.1% to 1.6% per year for women and 0.1% to 2.6% for men with CAC scores from 0 to 10 to > or =1,000, respectively (p <0.0001). For CHD death or MI, annual rates were 0.2% to 1.3% in women and 0.3% to 2.4% for men with low- to high-risk CAC scores. For women with a CAC score of 0, annual CHD death or MI rates were 0.16%, similar to that of men (p = 0.55). Summary relative risk ratios increased 4.9-fold (p = 0.006), 5.5-fold (p = 0.002), and 8.7-fold (p <0.0001) for mild-, moderate-, and high-risk CAC scores, respectively. A comparative analysis of gender differences showed no significant differences between women and men for mild- to high-risk CAC scores (p = 0.66), suggesting an equivalent ability to risk stratify by gender. In conclusion, this meta- and pooled analysis revealed that CAC screening is equally accurate in stratifying risk in women and men.

Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. · Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Building 2, Room 4A34, Washington, DC 20307-5001, USA. · Vasc Health Risk Manag. · Pubmed #17583186 links to  free full text

Abstract: BACKGROUND: We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy. This analysis examines the relationship between glycemic status and the effects of niacin on common carotid intima-media thickness (CIMT) and HDL cholesterol. METHODS: Post-hoc, subgroup analysis of ARBITER 2, a randomized, placebo-controlled trial of once-daily extended-release niacin (1000 mg) added to background statin therapy in 167 patients (mean age 67 years) with known coronary heart disease. The primary analysis was a comparison of the primary endpoint, the change in CIMT, between participants with either normal glycemic status, diabetes mellitus (DM) or the metabolic syndrome (MS). RESULTS: Baseline cardiovascular risk variables were significantly worse in those with abnormal glycemic status, particularly among subjects with MS. Niacin increased HDL-C to a similar degree (approximately 20%) across normals, DM and MS. Placebo-treated patients had the greatest CIMT progression, regardless of glycemic status. The lowest progression rate was observed in niacin treated patients with normal glycemic status. Among all niacin treated subjects, there was a significant linear relationship between change in CIMT and change in HDL-C (r = -0.16; p = 0.05), which was of similar magnitude in subgroups with normal glycemic status (r = -0.23; p = 0.08) and DM (r = -0.22; p = 0.17). In those with MS, there was no relationship between changes in HDL and CIMT, (r = 0.11; p = 0.44), whereas blood glucose was positive correlated to change in CIMT (r = 0.30; p = 0.04). In multivariable linear models controlling for MS characteristics and blood glucose changes, only the change in HDL independently predicted change in CIMT. CONCLUSIONS: During niacin treatment, increases in HDL-C are related to changes in CIMT in the setting of both normal glycemic status and diabetes mellitus.

Devine PJ, Turco MA, Taylor AJ. · Cardiology Service, Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. · Cardiovasc Drugs Ther. · Pubmed #17404825 No free full text.

Abstract: BACKGROUND: Recent evidence on the use of statin therapy indicates the potential for ultra-low levels of LDL-C to provide greater protection from recurrent coronary heart disease events. Guidelines for the treatment of lipid disorders were revised to indicate that an LDL-C treatment goal of 70 mg/dl was optional (NCEP ATPIII). In these same guidelines, low levels of HDL-C are also suggested but not specifically proscribed as a target of therapy. Recently ARBITER 2 (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2) has provided the first evidence of the potential of raising HDL-C with extended release niacin when added to statin monotherapy in secondary prevention. However, whether this approach would be superior to a strategy in which lower concentrations of LDL-C are targeted is unknown. MATERIALS AND METHODS: ARBITER 6-HALTS ( HDL and LDL Treatment Strategies) will be a randomized, parallel group, open-label study comparing HDL-C and LDL-C focused strategies of lipid treatments for their effects on atherosclerosis. Up to 400 subjects will be assigned to either intensified LDL-C lowering therapy with ezetimibe or HDL-C raising therapy with extended-release niacin. The primary endpoint is the mean change in the intima-media thickness of the common carotid artery after 14 months. Secondary endpoints include the change in lipid values and lipid subfractions, drug discontinuation due to adverse effects, change in quality of life, and a composite endpoint consisting of all major adverse cardiovascular events. CONCLUSION: ARBITER 6-HALTS will guide clinicians on whether a lipid treatment strategy of raising HDL-C or further LDL-C reduction is superior in the secondary prevention of coronary heart disease.

Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, Anonymous00384, Anonymous00385, Anonymous00386. · No affiliation provided · J Am Coll Cardiol. · Pubmed #17239724 No free full text.

This publication has no abstract.

Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, Harrington RA, Abrams J, Anderson JL, Bates ER, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Vogel RA, Wesley DJ, Anonymous00020, Anonymous00021, Anonymous00022. · No affiliation provided · Circulation. · Pubmed #17220398 links to  free full text

This publication has no abstract.